New Ray Medicine International Holding Limited (HKG:6108)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.214
+0.001 (0.47%)
Last updated: Mar 9, 2026, 2:42 PM HKT
-52.44%
Market Cap 42.93M
Revenue (ttm) 121.93M
Net Income (ttm) -34.38M
Shares Out 200.62M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,000
Average Volume 159,784
Open 0.214
Previous Close 0.213
Day's Range 0.214 - 0.214
52-Week Range 0.206 - 0.610
Beta -4.63
RSI 34.58
Earnings Date Mar 25, 2026

About HKG:6108

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People’s Republic of China. The company’s pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin α1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor rel... [Read more]

Sector Healthcare
Founded 2001
Employees 30
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6108
Full Company Profile

Financial Performance

In 2024, HKG:6108's revenue was 93.95 million, an increase of 87.31% compared to the previous year's 50.15 million. Losses were -31.01 million, 39.9% more than in 2023.

Financial Statements

News

There is no news available yet.